干扰素 β-1b 治疗多发性硬化症引发的活动性肺结核：四例病例报告及文献复习。
Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review.
机构信息
Neurology Department, Titu Maiorescu University, 040441 Bucharest, Romania.
Neurology, Carol Davila Central Military Emergency University Hospital, 010242 Bucharest, Romania.
出版信息
Medicina (Kaunas). 2020 Apr 24;56(4):202. doi: 10.3390/medicina56040202.
In this paper, we reported on four cases of severe pulmonary active tuberculosis in patients with multiple sclerosis (MS) undergoing interferon beta-1b (IFNβ-1b) therapy. Disease-modifying therapies (DMTs) in MS may increase the risk of developing active tuberculosis (TB) due to their impact on cellular immunity. Screening for latent infection with (LTBI) should be performed, not only for the newer DMTs (alemtuzumab, ocrelizumab) but also for IFNβ-1b, alongside better supervision of these patients.
本研究报道了 4 例多发性硬化（MS）患者在接受干扰素β-1b（IFNβ-1b）治疗期间发生严重的活动性肺结核（TB）的病例。MS 的疾病修正治疗（DMT）可能会因影响细胞免疫而增加发生活动性 TB 的风险。应进行潜伏性结核感染（LTBI）筛查，不仅对新型 DMT（阿仑单抗、奥瑞珠单抗）如此，对 IFNβ-1b 也是如此，同时还应对这些患者进行更好的监测。
Zotero 插件